Parabilis Medicines, Inc.’s Quiet Period Set To End on July 20th (NASDAQ:PBLS)

Parabilis Medicines’ (NASDAQ:PBLS) quiet period is set to end on Monday, July 20th. Parabilis Medicines had issued 33,500,000 shares in its public offering on June 10th. The total size of the offering was $670,000,000 based on an initial share price of $20.00. During the company’s quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analysts Forecast Growth

PBLS has been the subject of several research reports. Lifesci Capital upgraded shares of Parabilis Medicines to a “strong-buy” rating in a research report on Monday, July 6th. Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. Bank of America assumed coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set a “buy” rating and a $45.00 target price for the company. Zacks Research upgraded shares of Parabilis Medicines to a “hold” rating in a report on Tuesday, July 7th. Finally, Leerink Partners assumed coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $41.67.

Parabilis Medicines Price Performance

Shares of Parabilis Medicines stock opened at $30.57 on Monday. Parabilis Medicines has a 12-month low of $24.51 and a 12-month high of $34.47.

Insiders Place Their Bets

In related news, Director Alan Sebulsky purchased 12,500 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average price of $20.00 per share, with a total value of $250,000.00. Following the purchase, the director owned 12,500 shares of the company’s stock, valued at $250,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Guy Levy acquired 500,000 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $20.00 per share, for a total transaction of $10,000,000.00. Following the acquisition, the insider owned 1,027,000 shares in the company, valued at approximately $20,540,000. This trade represents a 94.88% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 530,000 shares of company stock valued at $10,723,528 in the last quarter.